NEWARK, DE — The global CCR6 antagonists market is entering a high-growth phase, expanding from USD 1.0 billion in 2026 to USD 4.0 billion by 2036, registering a CAGR of 12.0%, according to Future Market Insights (FMI). Growth is being driven by increasing adoption of targeted immunotherapies, rising prevalence of autoimmune and inflammatory diseases, and expanding clinical trial...